Eli Lilly invests $400M in biomanufacturing expansion in Indianapolis

Eli Lilly will invest $400 million to expand biomanufacturing capacity at its Lilly Technology Center campus in Indianapolis, Indiana. The investment will support production of diabetes medicines, including insulins and Trulicity, with capacity and technology upgrades.

“These investments will enhance our existing facilities that make insulin, provide additional capacity for our growing portfolio of diabetes medicines and provide initial capacity for future medicines.”bioprocessintl.com

• 2 sources
• bioprocessintl.comEli Lilly cites tax reform in biomanufacturing expansion - Bioprocess InsiderDan StantonNov 20, 2019
• assemblymag.comEli Lilly to Create 100 Jobs as it Adds Capacity ...By: Austin WeberNov 26, 2019

Summarized from public sources; check the original articles before acting on it.